Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $1.53 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.